Appili Therapeutics Inc. APLI.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 261.60K | 176.40K | 149.20K | 144.10K | 72.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 261.60K | 176.40K | 149.20K | 144.10K | 72.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 261.60K | 176.40K | 149.20K | 144.10K | 72.00K |
| SG&A Expenses | 2.07M | 1.79M | 1.75M | 1.89M | 1.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.99M | 4.90M | 4.53M | 5.49M | 6.45M |
| Operating Income | -4.73M | -4.72M | -4.38M | -5.34M | -6.38M |
| Income Before Tax | -3.32M | -2.98M | -2.07M | -1.78M | -1.63M |
| Income Tax Expenses | 67.50K | 84.60K | 74.00K | 59.90K | 35.40K |
| Earnings from Continuing Operations | -3.39 | -3.07 | -2.14 | -1.84 | -1.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.39M | -3.07M | -2.14M | -1.84M | -1.66M |
| EBIT | -4.73M | -4.72M | -4.38M | -5.34M | -6.38M |
| EBITDA | -4.72M | -4.71M | -4.37M | -5.33M | -6.37M |
| EPS Basic | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 491.78M | 480.68M | 492.16M | 485.06M | 485.06M |
| Average Diluted Shares Outstanding | 491.78M | 480.68M | 492.16M | 485.06M | 485.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |